I am a lipid biochemist-cell biologist determining the molecular mechanisms of disorders of lipid metabolism and developing treatments for such disorders. The diseases where lipid metabolism plays a key role include cardiovascular diseases (such as coronary artery disease), metabolic disorders (such as diabetes), some infectious diseases (such as HIV) and neurological disorders (such as Alzheimer disease).
Molecular Characterization Of SEIPIN Function: Implications For Lipogenesis And Adipogenesis
Funder
National Health and Medical Research Council
Funding Amount
$767,468.00
Summary
Obesity and type II diabetes have become a major health threat to Australians. This project aims to understand how fat is made and stored. Results from this research may lead to novel therapeutic strategies against obesity and diabetes.
Many drugs modulate the function of proteins imbedded in cell membranes. Extensive research has been undertaken to better understand drug interactions with these proteins to improve drug therapies, but there has been relatively little progress in understanding the role of the cell membrane. This project will investigate how the cell membrane influences protein function and then use this information to develop novel drugs for the treatment of neurological disorders.
Targeting Lipid Signalling Receptors To Promote Remyelination In Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$925,907.00
Summary
Multiple sclerosis is caused by the immune system mistakenly attacking and depleting myelin, the fatty substance that insulates neurons in our nervous system. To improve MS therapy and open up the possibility for functional recovery, we must develop drugs that protect and regenerate myelin. We will define how the loss of certain key biochemical signals promotes myelin loss in MS, and how drugs that restore those signals may be used to protect and regenerate myelin in people with the disease.
The Role Of Endothelial Lipase In High Density Lipoprotein Metabolism
Funder
National Health and Medical Research Council
Funding Amount
$130,550.00
Summary
Atherosclerosis is a major cause of death and disability in Australia. A high level of blood cholesterol increases the risk of developing atherosclerosis. This increase in risk is caused by the cholesterol that is carried in low density lipoproteins (LDL). However, not all cholesterol is bad. A proportion of the cholesterol in blood is carried in high density lipoproteins (HDL), which are powerful protectors against atherosclerosis. As not all HDL protect equally well against atherosclerosis, it ....Atherosclerosis is a major cause of death and disability in Australia. A high level of blood cholesterol increases the risk of developing atherosclerosis. This increase in risk is caused by the cholesterol that is carried in low density lipoproteins (LDL). However, not all cholesterol is bad. A proportion of the cholesterol in blood is carried in high density lipoproteins (HDL), which are powerful protectors against atherosclerosis. As not all HDL protect equally well against atherosclerosis, it is important to know how blood levels of HDL are regulated. In 1999 a new enzyme called endothelial lipase was discovered. Endothelial lipase dramatically decreases HDL levels in mice. The reason why this happens is not known. The main aims of this project are to work out how endothelial lipase decreases HDL levels and whether it decreases the levels of all HDL equally or whether it preferentially decreases the levels of certain types of HDL. The outcome of this project will establish how endothelial lipase affects the ability of HDL to protect against atherosclerosis in humans.Read moreRead less
Glycine Transport Inhibitors For The Treatment Of Pain
Funder
National Health and Medical Research Council
Funding Amount
$923,660.00
Summary
Chronic pain is particularly difficult to treat. Whilst currently used opioid drugs are effective in acute pain, they are either ineffective in chronic pain or have considerable side effects. In this project we will develop a new class of analgesics that have a different mechanism of action to traditional analgesics. It is hoped that these new drugs will provide long term pain relief without debilitating side effects.
The proposed research project involves a fundamental biochemical and biophysical investigation of a protein (ABCA4) intimately involved in the visual process. The precise role of ABCA4 in vision has not yet been elucidated, although evidence suggests a role as a lipid translocase in the retinal regenerative pathway. Our primary objective is to provide direct evidence for this putative role.
Altered Myelin Sphingolipid Homeostasis In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$629,532.00
Summary
Alzheimer’s Disease (AD) is the most common form of dementia, and its incidence is rising as the population ages. This project will provide a detailed analysis and explanation for the loss of particular lipid (fat) molecules that are essential for myelin integrity, in the brains of AD patients. Myelin is the insulating layer that surrounds brain cells, facilitating the transmission of electrical signals. This research will improve our understanding of how brain functions are impaired in AD.
A Molecular Investigation Into Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$628,152.00
Summary
Tuberculosis (TB) infection currently causes ~1.5 million deaths annually. Due to new survival features acquired by the causative agent (Mycobacterium tuberculosis), traditional TB drugs and vaccines are becoming inefficient. Mycobacterium tuberculosis has a protective lipid-dense cell wall that is targeted by our immune system. We aim to understand the mechanisms of the lipid-mediated immune response to TB in order to develop more effective strategies to combat this disease.
I am a neuroscientist-biochemist-cell biologist determining the mechanisms by which lipids and lipid transporters regulate neurodegeneration and vascular disease. I have recently developed a prototype drug that shows promise as a novel therapeutic approach for Alzheimer's disease.